JP2006503106A - 統合失調症を処置するためのヘテロ環式置換ピペラジン - Google Patents

統合失調症を処置するためのヘテロ環式置換ピペラジン Download PDF

Info

Publication number
JP2006503106A
JP2006503106A JP2004568902A JP2004568902A JP2006503106A JP 2006503106 A JP2006503106 A JP 2006503106A JP 2004568902 A JP2004568902 A JP 2004568902A JP 2004568902 A JP2004568902 A JP 2004568902A JP 2006503106 A JP2006503106 A JP 2006503106A
Authority
JP
Japan
Prior art keywords
disorder
dihydro
piperazin
quinolin
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004568902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006503106A5 (enExample
Inventor
トーニャ・リン・アンドレアーナ
スティーヴン・スン・ヨン・チョウ
ジェイムズ・マイクル・グレアム
トレイシー・フェイ・グレゴリー
ハリー・ラルフ・ハワード・ジュニア
ブライアン・エドワード・コーンバーグ
シャム・シュリードハール・ニーカム
デレク・アンドルー・プフルム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of JP2006503106A publication Critical patent/JP2006503106A/ja
Publication of JP2006503106A5 publication Critical patent/JP2006503106A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
JP2004568902A 2002-09-17 2003-09-05 統合失調症を処置するためのヘテロ環式置換ピペラジン Pending JP2006503106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41147502P 2002-09-17 2002-09-17
US41635502P 2002-10-04 2002-10-04
PCT/IB2003/003902 WO2004026864A1 (en) 2002-09-17 2003-09-05 Heterocyclic substituted piperazines for the treatment of schizophrenia

Publications (2)

Publication Number Publication Date
JP2006503106A true JP2006503106A (ja) 2006-01-26
JP2006503106A5 JP2006503106A5 (enExample) 2006-10-26

Family

ID=32033549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004568902A Pending JP2006503106A (ja) 2002-09-17 2003-09-05 統合失調症を処置するためのヘテロ環式置換ピペラジン

Country Status (25)

Country Link
US (1) US20040138230A1 (enExample)
EP (1) EP1546143A1 (enExample)
JP (1) JP2006503106A (enExample)
KR (1) KR20050057404A (enExample)
AP (1) AP2005003250A0 (enExample)
AR (1) AR041260A1 (enExample)
AU (1) AU2003263413A1 (enExample)
BR (1) BR0314393A (enExample)
CA (1) CA2499326A1 (enExample)
CO (1) CO5550472A2 (enExample)
EA (1) EA200500342A1 (enExample)
EC (1) ECSP055676A (enExample)
HR (1) HRP20050248A2 (enExample)
IS (1) IS7710A (enExample)
MA (1) MA27438A1 (enExample)
MX (1) MXPA05002007A (enExample)
NO (1) NO20051826L (enExample)
OA (1) OA12923A (enExample)
PA (1) PA8582601A1 (enExample)
PE (1) PE20050132A1 (enExample)
PL (1) PL375981A1 (enExample)
RS (1) RS20050195A (enExample)
TW (1) TW200409771A (enExample)
UY (1) UY27976A1 (enExample)
WO (1) WO2004026864A1 (enExample)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007091733A (ja) * 2005-08-31 2007-04-12 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2008239617A (ja) * 2007-02-27 2008-10-09 Otsuka Pharmaceut Co Ltd 医薬
JP2010528042A (ja) * 2007-05-21 2010-08-19 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
JP2011529090A (ja) * 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
JP2012502944A (ja) * 2008-09-22 2012-02-02 エフ．ホフマン−ラ ロシュ アーゲー ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬
JP2012531434A (ja) * 2009-06-25 2012-12-10 アルカーメス，インコーポレイテッド Ｎｈ酸性化合物のプロドラッグ
JP2013523749A (ja) * 2010-03-29 2013-06-17 オンコセラピー・サイエンス株式会社 三環化合物およびこれを含有するｐｂｋ阻害剤
JP2014144964A (ja) * 2014-03-26 2014-08-14 Jiangsu guohua investment co ltd アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
JP2018536652A (ja) * 2015-10-26 2018-12-13 エヌエイチダブリュエイ、ファーマ．コーポレイションＮｈｗａ Ｐｈａｒｍａ． Ｃｏｒｐｏｒａｔｉｏｎ 縮合複素環化合物誘導体およびその応用
JP2019500329A (ja) * 2015-11-20 2019-01-10 エヌエイチダブリュエイ、ファーマ．コーポレイションＮｈｗａ Ｐｈａｒｍａ． Ｃｏｒｐｏｒａｔｉｏｎ ラクタム化合物誘導体およびその応用
JPWO2020230802A1 (enExample) * 2019-05-14 2020-11-19

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2505397A1 (en) * 2002-11-08 2004-05-21 Warner-Lambert Company Llc Phenylalkyl and pyridylalkyl piperazine derivatives
BRPI0416739A (pt) * 2003-12-08 2007-01-16 Warner Lambert Co derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia
MXPA06007654A (es) * 2003-12-31 2006-09-04 Warner Lambert Co Derivados de piperidina n-sustituidos.
US20050256118A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
WO2006090273A2 (en) * 2005-02-22 2006-08-31 Warner-Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
WO2008015516A1 (en) * 2006-07-28 2008-02-07 Pfizer Products Inc. Fused tricyclic heterocycles for the treatment of schizophrenia
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
AR063302A1 (es) * 2006-10-13 2009-01-21 Otsuka Pharma Co Ltd Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla.
CA2723775A1 (en) 2008-05-08 2009-11-12 Allergan, Inc. Therapeutically useful substituted 1,7-diphenyl-1,2,3,5,6,7-hexahydropyrido[3,2,1-ij]quinoline compounds
US20090281322A1 (en) * 2008-05-08 2009-11-12 Allergan, Inc. THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS
CA2736724A1 (en) * 2008-09-23 2010-04-01 F.Hoffmann-La Roche Ag Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors
AU2014265021B2 (en) * 2009-06-25 2016-07-21 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
PT2445502T (pt) * 2009-06-25 2017-09-22 Alkermes Pharma Ireland Ltd Compostos heterocíclicos para o tratamento de distúrbios neurológicos e psicológicos
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
ES2972387T3 (es) 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds
ES2601457T3 (es) 2011-07-28 2017-02-15 Otsuka Pharmaceutical Co., Ltd. Método para producir compuestos de benzo[b]tiofeno
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
WO2013088255A1 (en) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
WO2013142202A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
JP6654042B2 (ja) 2012-09-19 2020-02-26 アルカームス ファーマ アイルランド リミテッド 貯蔵安定性が改善された医薬組成物
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
AU2019230014B2 (en) 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
WO2021098737A1 (zh) * 2019-11-18 2021-05-27 上海枢境生物科技有限公司 稠和杂环类衍生物及其应用
EP4382521A4 (en) * 2021-08-05 2025-01-01 Shujing Biopharma Co., Ltd Regulator containing tricyclic derivative, preparation method therefor and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3706427A1 (de) * 1987-02-27 1988-09-08 Boehringer Mannheim Gmbh Neue substituierte 3h-indole, zwischenprodukte, verfahren zu ihrer herstellung sowie arzneimittel
GB8723763D0 (en) * 1987-10-09 1987-11-11 Hydro Tech Ltd Liquid flow control device
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5776963A (en) * 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JP2768981B2 (ja) * 1989-06-22 1998-06-25 シャープ株式会社 光メモリ素子
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
US5350747A (en) * 1989-07-07 1994-09-27 Pfizer Inc Heteroaryl piperazine antipsychotic agents
US5147881A (en) * 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
MX9201991A (es) * 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
TW300219B (enExample) * 1991-09-14 1997-03-11 Hoechst Ag
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
DE19746612A1 (de) * 1997-10-22 1999-04-29 Basf Ag 2-Substituierte 1,2-Benzisothiazol-Derivate, ihre Herstellung und Verwendung
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
HK1047582B (zh) * 1999-06-23 2005-03-04 萨诺费－阿文蒂斯德国有限公司 取代的苯並咪唑

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007091733A (ja) * 2005-08-31 2007-04-12 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2008239617A (ja) * 2007-02-27 2008-10-09 Otsuka Pharmaceut Co Ltd 医薬
JP2010528042A (ja) * 2007-05-21 2010-08-19 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
JP2011529090A (ja) * 2008-07-28 2011-12-01 江蘇国華投資有限公司 アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
JP2012502944A (ja) * 2008-09-22 2012-02-02 エフ．ホフマン−ラ ロシュ アーゲー ピペラジンｄ３及び５−ｈｔ２ａ受容体調節薬
JP2012531434A (ja) * 2009-06-25 2012-12-10 アルカーメス，インコーポレイテッド Ｎｈ酸性化合物のプロドラッグ
JP2013523749A (ja) * 2010-03-29 2013-06-17 オンコセラピー・サイエンス株式会社 三環化合物およびこれを含有するｐｂｋ阻害剤
JP2014144964A (ja) * 2014-03-26 2014-08-14 Jiangsu guohua investment co ltd アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
JP2018536652A (ja) * 2015-10-26 2018-12-13 エヌエイチダブリュエイ、ファーマ．コーポレイションＮｈｗａ Ｐｈａｒｍａ． Ｃｏｒｐｏｒａｔｉｏｎ 縮合複素環化合物誘導体およびその応用
JP2019500329A (ja) * 2015-11-20 2019-01-10 エヌエイチダブリュエイ、ファーマ．コーポレイションＮｈｗａ Ｐｈａｒｍａ． Ｃｏｒｐｏｒａｔｉｏｎ ラクタム化合物誘導体およびその応用
US10501452B2 (en) 2015-11-20 2019-12-10 Nhwa Pharma. Corporation Lactam compound derivative and application thereof
JP2020158520A (ja) * 2015-11-20 2020-10-01 エヌエイチダブリュエイ、ファーマ．コーポレイションＮｈｗａ Ｐｈａｒｍａ． Ｃｏｒｐｏｒａｔｉｏｎ ラクタム化合物誘導体およびその応用
JP7035118B2 (ja) 2015-11-20 2022-03-14 エヌエイチダブリュエイ、ファーマ．コーポレイション ラクタム化合物誘導体およびその応用
JPWO2020230802A1 (enExample) * 2019-05-14 2020-11-19
WO2020230802A1 (ja) * 2019-05-14 2020-11-19 杏林製薬株式会社 ４－オキソピロリジン－３－カルボン酸アミド誘導体の製造方法

Also Published As

Publication number Publication date
BR0314393A (pt) 2005-07-19
UY27976A1 (es) 2004-04-30
PA8582601A1 (es) 2004-05-26
CA2499326A1 (en) 2004-04-01
AU2003263413A1 (en) 2004-04-08
TW200409771A (en) 2004-06-16
WO2004026864A1 (en) 2004-04-01
NO20051826L (no) 2005-04-15
EA200500342A1 (ru) 2005-08-25
PE20050132A1 (es) 2005-03-21
RS20050195A (sr) 2007-08-03
PL375981A1 (en) 2005-12-12
CO5550472A2 (es) 2005-08-31
KR20050057404A (ko) 2005-06-16
IS7710A (is) 2005-02-24
MXPA05002007A (es) 2005-04-28
ECSP055676A (es) 2005-07-06
AR041260A1 (es) 2005-05-11
OA12923A (en) 2006-10-13
EP1546143A1 (en) 2005-06-29
HRP20050248A2 (en) 2005-10-31
AP2005003250A0 (en) 2005-03-31
US20040138230A1 (en) 2004-07-15
MA27438A1 (fr) 2005-07-01

Similar Documents

Publication Publication Date Title
US20040138230A1 (en) Heterocyclic substituted piperazines for the treatment of schizophrenia
CA2596636C (en) Heterocyclyl substituted phenyl methanones as inhibitors of the glycine transporter 1
EP0409435B1 (en) Heteroaryl piperazine antipsychotic agents
JP2010536789A (ja) ５−ｈｔ６受容体親和性を有する３’置換化合物
JP2007517014A (ja) Ｎ−置換ピペリジン及びピペラジン誘導体
WO1997047601A1 (en) Fused heterocyclic compounds and medicinal uses thereof
WO2010002802A1 (en) Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US6303614B1 (en) Tetrahydro gamma-carbolines
JP2010519226A (ja) ５−ｈｔ６受容体親和性を有する６’位置換インドール及びインダゾール誘導体
CN1326855C (zh) 稠环吡唑衍生物
CA2316388C (en) Tetrahydrobenzindole derivative
US20040067960A1 (en) Heterocyclic substituted piperazines for the treatment of schizophrenia
WO2006051394A1 (en) Azabenzoxazoles for the treatment of cns disorders
WO2006090272A1 (en) Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
WO2006051410A1 (en) Azabenzoxazoles for the treatment of cns disorders
US20060234997A1 (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
TW589312B (en) Aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression
US6245778B1 (en) 1,6-naphthyridine anti-convulsants
MXPA05003658A (es) Derivados de piperazina sustituidos con oxindol.
US20060166974A1 (en) Azabenzoxazoles for the treatment of CNS disorders
MXPA00002342A (en) Tetrahydro gamma-carbolines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100216

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100713